-
1.
公开(公告)号:US07598250B2
公开(公告)日:2009-10-06
申请号:US10911030
申请日:2004-08-04
申请人: Jared N. Cumming , Ying Huang , Guoqing Li , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Jianping Pan , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie
发明人: Jared N. Cumming , Ying Huang , Guoqing Li , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Jianping Pan , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie
IPC分类号: A61K31/506 , A61K31/496 , C07D403/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/14
CPC分类号: C04B35/632 , C07D207/277 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14
摘要: Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is X is —O—, —C(R14)2— or —N(R)—; Z is —C(R14)2— or —N(R)—; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, —CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, —OR35, —N(R24)(R25) or —SR35; R41 is alkyl, cycloalkyl, —SO2(alkyl), —C(O)-alkyl, —C(O)-cycloalkyl or -alkyl-NH—C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I.Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.
摘要翻译: 公开了下式的新化合物或其药学上可接受的盐或溶剂合物,其中R 1是X是-O - , - C(R 14)2 - 或-N(R) - ; Z是-C(R 14)2 - 或-N(R) - ; t为0,1,2或3; 每个R和R 2独立地为H,烷基,环烷基,环烷基烷基,芳基,杂芳基,杂环烷基,芳基烷基,杂芳基烷基,杂环烷基烷基,烯基或炔基; 每个R 14是H,烷基,烯基,炔基,卤素,-CN,卤代烷基,环烷基,环烷基烷基,芳基,杂芳基,杂环烷基,芳基烷基,杂芳基烷基,杂环烷基烷基,-OR 35,-N(R 24)(R 25)或-SR 35; R41是烷基,环烷基,-SO2(烷基),-C(O) - 烷基,-C(O) - 环烷基或 - 烷基-NH-C(O)CH3; 其余变量如本说明书中所定义。 还公开了包含式I化合物的药物组合物和用式I化合物治疗认知障碍或神经变性疾病的方法。还公开了药物组合物和治疗方法,其包含式I化合物与用于治疗认知或神经变性的其它药剂 疾病
-
2.
公开(公告)号:US20090312341A1
公开(公告)日:2009-12-17
申请号:US12490884
申请日:2009-06-24
申请人: Jared N. Cumming , Ying Huang , Guoqing Li , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Jianping Pan , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie
发明人: Jared N. Cumming , Ying Huang , Guoqing Li , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Jianping Pan , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie
IPC分类号: A61K31/496 , C12N9/99 , A61P25/28
CPC分类号: C04B35/632 , C07D207/277 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/14
摘要: Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is X is —O—, —C(R14)2— or —N(R)—; Z is —C(R14)2— or —N(R)—; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, —CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, —OR35, —N(R24) (R25) or —SR35; R41 is alkyl, cycloalkyl, —SO2(alkyl), —C(O)-alkyl, —C(O)-cycloalkyl or -alkyl-NH—C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula I.Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.
摘要翻译: 公开了下式的新化合物或其药学上可接受的盐或溶剂合物,其中R 1是X是-O - , - C(R 14)2 - 或-N(R) - ; Z是-C(R 14)2 - 或-N(R) - ; t为0,1,2或3; 每个R和R 2独立地为H,烷基,环烷基,环烷基烷基,芳基,杂芳基,杂环烷基,芳基烷基,杂芳基烷基,杂环烷基烷基,烯基或炔基; 每个R 14是H,烷基,烯基,炔基,卤素,-CN,卤代烷基,环烷基,环烷基烷基,芳基,杂芳基,杂环烷基,芳基烷基,杂芳基烷基,杂环烷基烷基,-OR 35,-N(R 24)(R 25)或-SR 35; R41是烷基,环烷基,-SO2(烷基),-C(O) - 烷基,-C(O) - 环烷基或 - 烷基-NH-C(O)CH3; 其余变量如本说明书中所定义。 还公开了包含式I化合物的药物组合物和用式I化合物治疗认知障碍或神经变性疾病的方法。还公开了药物组合物和治疗方法,其包含式I化合物与用于治疗认知或神经变性的其它药剂 疾病
-
3.
公开(公告)号:US08278334B2
公开(公告)日:2012-10-02
申请号:US12641952
申请日:2009-12-18
申请人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
发明人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
IPC分类号: A61K31/4439 , A61K31/40 , A61K31/4025 , C07D207/12 , C07D401/06 , C07D403/12
CPC分类号: C07D243/08 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D209/52 , C07D211/26 , C07D211/46 , C07D217/18 , C07D233/32 , C07D241/04 , C07D241/08 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/06 , C07D409/12 , C07D413/06
摘要: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
摘要翻译: 公开了下式的化合物或其药学上可接受的盐或溶剂化物,其中R1是R是-C(O)-N(R27)(R28),或其余的变量如说明书中所定义。 还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。 还公开了治疗认知或神经变性疾病的药物组合物和方法,其包含式I化合物与除式I以外的分泌抑制剂抑制剂,HMG-CoA还原酶抑制剂,γ-分泌酶抑制剂,非 - 甾族抗炎药,N-甲基-D-天冬氨酸受体拮抗剂,胆碱酯酶抑制剂或抗淀粉样蛋白抗体。
-
4.
公开(公告)号:US07662816B2
公开(公告)日:2010-02-16
申请号:US10910987
申请日:2004-08-04
申请人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
发明人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
IPC分类号: A61K31/496 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D211/34 , C07D207/16 , C07D207/26 , C07D243/08 , C07D413/12
CPC分类号: C07D243/08 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D209/52 , C07D211/26 , C07D211/46 , C07D217/18 , C07D233/32 , C07D241/04 , C07D241/08 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/06 , C07D409/12 , C07D413/06
摘要: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
摘要翻译: 公开了下式的化合物或其药学上可接受的盐或溶剂化物,其中R1是R是-C(O)-N(R27)(R28),或其余的变量如说明书中所定义。 还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。 还公开了治疗认知或神经变性疾病的药物组合物和方法,其包含式I化合物与除式I以外的β-分泌酶抑制剂,HMG-CoA还原酶抑制剂,γ-分泌酶抑制剂, 甾族抗炎剂,N-甲基-D-天冬氨酸受体拮抗剂,胆碱酯酶抑制剂或抗淀粉样蛋白抗体。
-
5.
公开(公告)号:US20100152138A1
公开(公告)日:2010-06-17
申请号:US12641952
申请日:2009-12-18
申请人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X.H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
发明人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voigt , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X.H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
IPC分类号: A61K31/4015 , C07D207/12 , C07D217/24 , C07D413/12 , C07D243/08 , A61K31/47 , A61K31/675 , A61K31/397 , A61K31/5377 , A61K31/551 , A61P25/28
CPC分类号: C07D243/08 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D209/52 , C07D211/26 , C07D211/46 , C07D217/18 , C07D233/32 , C07D241/04 , C07D241/08 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/06 , C07D409/12 , C07D413/06
摘要: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification.Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
摘要翻译: 公开了下式的化合物或其药学上可接受的盐或溶剂化物,其中R1是R是-C(O)-N(R27)(R28),或其余的变量如说明书中所定义。 还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。 还公开了治疗认知或神经变性疾病的药物组合物和方法,其包含式I化合物与除式I以外的分泌抑制剂抑制剂,HMG-CoA还原酶抑制剂,γ-分泌酶抑制剂,非 - 甾族抗炎药,N-甲基-D-天冬氨酸受体拮抗剂,胆碱酯酶抑制剂或抗淀粉样蛋白抗体。
-
6.
公开(公告)号:US08623867B2
公开(公告)日:2014-01-07
申请号:US13610162
申请日:2012-09-11
申请人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voight , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey H. Lowrie , Kurt W. Saionz , Suresh D. Babu
发明人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voight , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X. H. Le , Jeffrey H. Lowrie , Kurt W. Saionz , Suresh D. Babu
IPC分类号: A61K31/445 , A61K31/4458 , A61K31/454 , A61K31/4545 , A61K31/5377 , C07D295/027 , C07D401/06 , C07D401/12 , C07D413/12
CPC分类号: C07D243/08 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D209/52 , C07D211/26 , C07D211/46 , C07D217/18 , C07D233/32 , C07D241/04 , C07D241/08 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/06 , C07D409/12 , C07D413/06
摘要: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
摘要翻译: 公开了下式的化合物或其药学上可接受的盐或溶剂化物,其中R1是R是-C(O)-N(R27)(R28),或其余的变量如说明书中所定义。 还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。 还公开了治疗认知或神经变性疾病的药物组合物和方法,其包含式I化合物与除式I以外的β-分泌酶抑制剂,HMG-CoA还原酶抑制剂,γ-分泌酶抑制剂, 甾族抗炎剂,N-甲基-D-天冬氨酸受体拮抗剂,胆碱酯酶抑制剂或抗淀粉样蛋白抗体。
-
7.
公开(公告)号:US20130004518A1
公开(公告)日:2013-01-03
申请号:US13610162
申请日:2012-09-11
申请人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voight , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X.H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
发明人: Jared N. Cumming , Ulrich Iserloh , Andrew Stamford , Corey Strickland , Johannes H. Voight , Yusheng Wu , Ying Huang , Yan Xia , Samuel Chackalamannil , Tao Guo , Douglas W. Hobbs , Thuy X.H. Le , Jeffrey F. Lowrie , Kurt W. Saionz , Suresh D. Babu
IPC分类号: C07D207/09 , C07F9/572 , A61K31/675 , C07D217/18 , A61K31/472 , C07F9/62 , C07D207/12 , A61K31/4025 , C07D401/14 , A61K31/4439 , C07D205/04 , A61K31/397 , C07D211/26 , A61K31/4458 , C07D211/46 , A61K31/445 , C07D413/12 , A61K31/5377 , C07D401/12 , A61K31/454 , C07D401/04 , A61K31/451 , A61K31/4545 , C07D241/08 , A61K31/495 , C07D403/12 , A61K31/496 , C07D241/24 , C07D413/06 , C07D243/08 , A61K31/551 , A61K39/395 , A61K31/5415 , A61K31/505 , A61P25/00 , A61P25/28 , A61P29/00 , A61K31/40
CPC分类号: C07D243/08 , C07D205/04 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D209/52 , C07D211/26 , C07D211/46 , C07D217/18 , C07D233/32 , C07D241/04 , C07D241/08 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/12 , C07D403/14 , C07D409/06 , C07D409/12 , C07D413/06
摘要: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, whereinR1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification.Also disclosed are pharmaceutical compositions comprising the compounds of formula I.Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease.Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.
摘要翻译: 公开了下式的化合物或其药学上可接受的盐或溶剂化物,其中R1是R是-C(O)-N(R27)(R28),或其余的变量如说明书中所定义。 还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。 还公开了治疗认知或神经变性疾病的药物组合物和方法,其包含式I化合物与除式I以外的分泌抑制剂抑制剂,HMG-CoA还原酶抑制剂,γ-分泌酶抑制剂,非 - 甾族抗炎药,N-甲基-D-天冬氨酸受体拮抗剂,胆碱酯酶抑制剂或抗淀粉样蛋白抗体。
-
公开(公告)号:US07256186B2
公开(公告)日:2007-08-14
申请号:US10941440
申请日:2004-09-15
申请人: Dimitri A. Pissarntiski , Hubert B. Josien , Elizabeth M. Smith , John W. Clader , Theodros Asberom , Tao Guo , Douglas W. Hobbs
发明人: Dimitri A. Pissarntiski , Hubert B. Josien , Elizabeth M. Smith , John W. Clader , Theodros Asberom , Tao Guo , Douglas W. Hobbs
IPC分类号: C07D211/08 , C07D207/46 , C07D205/00 , C07D279/00 , A01N43/00
CPC分类号: C07D401/14 , C07D211/96 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D451/06 , C07D471/04 , C07D471/10 , C07D491/10
摘要: This invention discloses novel gamma secretase inhibitors of the formula: wherein: R1 is a substituted aryl or substituted heteroaryl group; R2 is an R1 group, alkyl, —XC(O)Y, alkylene-XC(O)Y, cycloalkylene-X—C(O)—Y, —CH—X—C(O)—NR3—Y or —CH—X—C(O)—Y, wherein X and Y are as defined herein; each R3 and each R3A are independently H, or alkyl; R11 is aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, or alkoxyalkyl. Also disclosed is a method of treating Alzheimer's Disease using one or more compounds of the invention.
摘要翻译: 本发明公开了下式的新型γ分泌酶抑制剂:其中:R 1是取代的芳基或取代的杂芳基; R 2是R 1基团,烷基,-XC(O)Y,亚烷基-XC(O)Y,亚环烷基-XC(O)-Y,-CH -XC(O)-NR 3 -Y或-CH-XC(O)-Y,其中X和Y如本文所定义; 每个R 3和R 3各自独立地为H或烷基; R 11是芳基,杂芳基,烷基,环烷基,芳基烷基,芳基环烷基,杂芳基烷基,杂芳基环烷基,芳基杂环烷基或烷氧基烷基。 还公开了使用一种或多种本发明化合物治疗阿尔茨海默病的方法。
-
公开(公告)号:US07208602B2
公开(公告)日:2007-04-24
申请号:US10358898
申请日:2003-02-05
申请人: Dmitri A. Pissarnitski , Hubert B. Josien , Elizabeth M. Smith , John W. Clader , Theodros Asberom , Tao Guo , Douglas W. Hobbs
发明人: Dmitri A. Pissarnitski , Hubert B. Josien , Elizabeth M. Smith , John W. Clader , Theodros Asberom , Tao Guo , Douglas W. Hobbs
IPC分类号: C07D211/08 , C07D207/46 , C07D205/00 , C07D279/00 , A01N43/00
CPC分类号: C07D401/12 , C07D211/96 , C07D401/14 , C07D409/12 , C07D471/10
摘要: This invention discloses novel gamma secretase inhibitors of the formula: wherein: R1 is a substituted aryl or substituted heteroaryl group; R2 is an R1 group, alkyl, —X(CO)Y, or alkylene-X(CO)Y wherein X and Y are as defined herein; each R3 and each R3A are independently H, or alkyl; R11 is aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, or alkoxyalkyl. Also disclosed is a method of treating Alzheimer's Disease using one or more compounds of the invention.
摘要翻译: 本发明公开了下式的新型γ分泌酶抑制剂:其中:R 1是取代的芳基或取代的杂芳基; R 2是R 1基团,烷基,-X(CO)Y或亚烷基-X(CO)Y,其中X和Y如本文所定义; 每个R 3和R 3各自独立地为H或烷基; R 11是芳基,杂芳基,烷基,环烷基,芳基烷基,芳基环烷基,杂芳基烷基,杂芳基环烷基,芳基杂环烷基或烷氧基烷基。 还公开了使用一种或多种本发明化合物治疗阿尔茨海默病的方法。
-
公开(公告)号:US06887889B2
公开(公告)日:2005-05-03
申请号:US10120080
申请日:2002-04-10
申请人: Douglas W. Hobbs , Tao Guo , Rachael C. Hunter , Huizhong Gu , Suresh D. Babu , Yuefei Shao
发明人: Douglas W. Hobbs , Tao Guo , Rachael C. Hunter , Huizhong Gu , Suresh D. Babu , Yuefei Shao
IPC分类号: A61K31/438 , A61K31/4433 , A61K31/445 , A61K31/4525 , A61K31/454 , A61K31/4545 , A61K45/00 , A61P3/04 , A61P5/14 , A61P43/00 , C07D211/26 , C07D211/32 , C07D211/34 , C07D211/64 , C07D401/06 , C07D401/10 , C07D405/04 , C07D405/10 , C07D405/12 , C07D471/10 , C07D221/26
CPC分类号: C07D401/10 , C07D211/26 , C07D405/04 , C07D405/10 , C07D405/12 , C07D471/10
摘要: In one embodiment, this invention provides a novel class of compounds as antagonists of the MCH receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration or one or more of diseases associated with the MCH receptor. An illustrative inventive compound is shown below:
摘要翻译: 在一个实施方案中,本发明提供了一类新颖的化合物作为MCH受体的拮抗剂,制备此类化合物的方法,含有一种或多种化合物的药物组合物,制备包含一种或多种此类化合物的药物制剂的方法,以及 治疗,预防或改善或与MCH受体相关的一种或多种疾病。 示例性的本发明化合物如下所示:
-
-
-
-
-
-
-
-
-